Jpmorgan Chase & CO Halozyme Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

$1.27 Trillion
Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 2,474,825 shares of HALO stock, worth $139 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

2,474,825

Previous 2,387,489 3.66%

Holding current value

$139 Million

Previous $114 Million 38.35%

% of portfolio

0.01%

Previous 0.01%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	BUY	$47.74 - $65.16 $4.17 Million - $5.69 Million	87,336 Added 3.66%	2,474,825 $158 Million
Q4 2024 Feb 12, 2025	SELL	$42.57 - $61.09 $20.3 Million - $29.2 Million	-477,368 Reduced 16.66%	2,387,489 $114 Million
Q3 2024 Dec 26, 2024	SELL	$51.3 - $64.42 $10.6 Million - $13.3 Million	-206,997 Reduced 6.74%	2,864,857 $164 Million
Q3 2024 Nov 08, 2024	SELL	$51.3 - $64.42 $10.6 Million - $13.3 Million	-206,997 Reduced 6.74%	2,864,857 $164 Million
Q2 2024 Dec 26, 2024	BUY	$37.81 - $52.4 $7.83 Million - $10.8 Million	206,997 Added 7.23%	3,071,854 $161 Million
Q2 2024 Aug 12, 2024	SELL	$37.81 - $52.4 $6.38 Million - $8.84 Million	-168,643 Reduced 5.2%	3,071,854 $161 Million
Q1 2024 Dec 26, 2024	BUY	$33.68 - $41.95 $12.7 Million - $15.8 Million	375,640 Added 13.11%	3,240,497 $132 Million
Q1 2024 May 10, 2024	BUY	$33.68 - $41.95 $4.94 Million - $6.15 Million	146,565 Added 4.74%	3,240,497 $132 Million
Q4 2023 Dec 26, 2024	BUY	$33.32 - $42.1 $7.63 Million - $9.64 Million	229,075 Added 8.0%	3,093,932 $114 Million
Q4 2023 Feb 12, 2024	SELL	$33.32 - $42.1 $2.31 Million - $2.92 Million	-69,333 Reduced 2.19%	3,093,932 $114 Million
Q3 2023 Nov 14, 2023	SELL	$36.46 - $44.03 $12.1 Million - $14.6 Million	-331,830 Reduced 9.49%	3,163,265 $121 Million
Q2 2023 Aug 11, 2023	SELL	$30.28 - $38.74 $838,180 - $1.07 Million	-27,681 Reduced 0.79%	3,495,095 $126 Million
Q1 2023 May 18, 2023	BUY	$32.86 - $55.7 $11 Million - $18.6 Million	334,418 Added 10.49%	3,522,776 $135 Million
Q1 2023 May 11, 2023	SELL	$32.86 - $55.7 $1.3 Million - $2.2 Million	-39,419 Reduced 1.22%	3,188,358 $122 Million
Q4 2022 Feb 13, 2023	SELL	$40.06 - $59.44 $28.3 Million - $41.9 Million	-705,249 Reduced 17.93%	3,227,777 $184 Million
Q3 2022 Nov 14, 2022	SELL	$38.53 - $51.78 $6 Million - $8.06 Million	-155,616 Reduced 3.81%	3,933,026 $156 Million
Q2 2022 Aug 11, 2022	SELL	$37.35 - $48.3 $35.5 Million - $45.9 Million	-951,129 Reduced 18.87%	4,088,642 $180 Million
Q1 2022 May 11, 2022	SELL	$31.97 - $41.06 $2.77 Million - $3.55 Million	-86,530 Reduced 1.69%	5,039,771 $201 Million
Q4 2021 Feb 10, 2022	SELL	$31.82 - $40.75 $4.4 Million - $5.63 Million	-138,138 Reduced 2.62%	5,126,301 $206 Million
Q3 2021 Nov 12, 2021	BUY	$38.47 - $46.42 $203 Million - $244 Million	5,264,439 New	5,264,439 $214 Million

Others Institutions Holding HALO

# of Institutions

595

Shares Held

124M

Call Options Held

320K

Put Options Held

113K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $7.81B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Halozyme Therapeutics, Inc. Transaction History